from TGEV that had been held at 4°C for 20 d before extraction at 2°C and 100°C in 1% SDS. The 60–70S complex seems to be intact, but, on melting, the complex liberates only small fragments of RNA of approximately 4S (Fig. 3h). This suggests that the virus preparations have an associated ribonuclease capable of producing breaks in the 35S strand while they are complexed in the 60-70S form. Whether the large amount of 4S RNA detected in all HEV preparations so far examined (Fig. 3e–f) represents degraded viral RNA or host tRNA associated with the virions is not known.

Our inability to detect protein in the 60–70S RNA complex from TGEV does not exclude the possibility that there is a very small amount that is dissociating from the RNA at elevated temperatures in the presence of SDS. The similarity of behaviour and size between the coronaviral RNA and RSV RNA, together with the liberation of 4S RNA on melting suggests strongly that the TGEV and HEV 60–70S complex is held together by RNA–RNA interactions as is the RNA from oncornaviruses. We hope to characterise further the 60–70S complex and determine whether the viral 4S component is in fact host tRNA. Although the replication of these two groups of viruses is fundamentally different, the coronaviruses being entirely cytoplasmic in contrast to the essential nuclear phase of the oncornaviruses, a similarity in the structure of the genomes of the two groups raises interesting implications for the phylogeny of the RNA tumour viruses.

We thank Mrs Brenda V. Pike for assistance and Dr. S. Martin, Imperial Cancer Research Fund Laboratories, London, for the gift of 3H-uridine-labelled RSV RNA. One of us (T.M.W.) was in receipt of a British Council Scholarship.

D. J. GARWES
D. H. POCOCK

Department of Microbiology,
Institute for Research on Animal Diseases,
Agricultural Research Council,
Compton, Newbury,
Berkshire RG16 0NN, UK

T. M. WHASZKA

The Veterinary Research Institute,
Al Partyzantow 37,
24–100 Palaowy, Poland

Received June 20; accepted August 20, 1975.

1 Celetti, E., Ristic, M., and von Lehmden-Matsin, A. A., Am. J. Vet. Res., 29, 1603–1612 (1968).
2 Tannock, G. A., Arch. ext. Virusforsch., 43, 259–271 (1973).
3 Misra, N. K., and Ryon, W. L., Am. J. Vet. Res., 34, 185–188 (1973).
4 Waterman, H., Reese, P., and Alexander, D. J., Arch. Virol., 47, 259–286 (1975).
5 Garwes, D. J., and Pocock, D. H., J. gen. Virol. (in the press).
6 Foster, R. W., Viral Immunol., 59, 599–609 (1974).
7 Duesberg, P. H., Proc. natn. Acad. Sci. U.S.A., 60, 1511–1518 (1968).

Presence of factor VIII-related antigen in blood platelets of patients with Von Willebrand’s disease

Von Willebrand’s disease (VWD) is an autosomally inherited disorder characterised by low factor VIII activity (antihaemophilic factor, AHF), prolonged bleeding time, reduced retention of platelets in a glass bead column and abnormal distocetin-induced platelet aggregation. The prolonged bleeding time in VWD has been attributed to the absence of a plasma factor, the von Willebrand factor (VWF), as shown by a correction of the bleeding time after infusion of normal and haemophilic plasmas1. Addition of purified factor VIII in vitro specifically corrects the abnormal platelet retention and ristocetin aggregation in VWD2; whereas transfusion of similar material into dogs with VWD also corrects the prolonged bleeding time (B.N.B., W. J. Dodds, J. A. van Mourik, J.J.S. and W. P. Webster, unpublished). This led to the suggestion that factor VIII is closely related if not identical to VWF, although dissociation of factor VIII-related activity from factor VIII-related antigen (F VIII-RA) is observed in certain conditions3. The plasma concentration of F VIII-RA is usually reduced in VWD suggesting a reduced synthesis of factor VIII (VWF)4. In contrast to this we now report the presence of normal concentrations of F VIII-RA in platelets of patients with VWD. This F VIII-RA supported aggregation induced by ristocetin in a washed platelet system5, a factor of VWF which has been attributed to VWF activity.

Human blood platelets were washed according to the method of Karpatkin6. ACD-blood was centrifuged (10 min, 200g, 20°C). Platelet rich plasma was diluted in 5 volumes of Krebs-Ringer buffer (pH 7.4) containing 9 mM Na2EDTA. After centrifugation (15 min, 1,000g, 4°C), the platelets were washed once in Krebs–Ringer buffer containing 9 mM Na2EDTA and twice in Krebs–Ringer buffer containing 1 mM Na2EDTA. The platelet pellet was finally resuspended in Krebs–Ringer buffer containing 30 mM glucose and 1 mM e-amino caproic acid. In the final washing fluid the protein content was lower than 50 μg ml−1 (ref. 11), and the concentration of F VIII-RA, measured by electrophooimmunoassay, was below 0.05 U ml−1 (ref. 12). 1 U F VIII-RA was defined as the amount present in 1 ml pooled normal plasma prepared from 40 healthy subjects13. In the final suspension (1×1010–3×1011 platelets μl−1) the platelets were disrupted by freezing and thawing (four times) followed by centrifugation (60 min, 30,000g, 4°C).

Ten suspensions of normal human platelets were tested. The concentration of F VIII-RA detected in the supernatant was 0.15 U mg−1 platelet protein (range 0.11–0.25) or 43 U 1010 platelets (range 19–94). Expressed per platelet (ref. 13) the concentration of F VIII-RA was 60 times (range 21–156) higher than that in plasma. Similar values were reported by Nachman and Jaffe14.

Platelet F VIII-RA showed a reaction of identity with plasma F VIII-RA, when tested in immunodiffusion using a rabbit anti-factor VIII serum and the antisera raised against the low ionic strength components (ref. 15 and B.N.B., J. van Mourik, S. de G., J.M.H.-H. and J.J.S., unpublished). Cross-immunoelectrophoretic analysis revealed an electrophoretic mobility comparable with that of plasma F VIII-RA.

Howard et al.15 quantitated F VIII-RA on intact washed normal platelets and concluded that F VIII-RA was firmly bound to the membrane fraction. A similar conclusion was reached by Bloom16 using an immunofluorescent technique. On the other hand, the localisation of F VIII-RA throughout the megakaryocytic cytoplasm is in agreement with its localisation inside the platelet17. Nachman and Jaffe14 reported the presence of F VIII-RA in subcellular membrane and granule fractions. We examined this localisation by a previously described indirect immunofluorescent technique17. Suspensions of intact washed platelets were incubated with antifactor VIII in suspension, washed again, and incubated with fluorescein isothiocyanate labelled horse anti-rabbit globulin (Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam). A drop of this suspension was studied under the fluorescence microscope. Most platelets were unstained, whereas a vivid granular staining was obtained after disruption of membranes by air drying of a drop of the same platelet suspension on a glass slide. The specificity tests have been described in detail elsewhere18. Staining with normal rabbit serum instead of with antifactor VIII was used as a control. The difference between staining in suspension or staining after air drying suggests that F VIII-RA is present inside the platelets.

In agreement with the results of Howard15 and Nachman and Jaffe14 no factor VIII activity could be detected in
Table 1. All patients except No. 10, who was considered to manifest VWD type II (ref. 24), had low or absent F VIII-RA in their plasma and fulfilled the criteria of VWD. In two patients (Nos 4 and 11) no F VIII-RA was detected in the platelets, whereas all other patients had normal concentrations of F VIII-RA in their platelets. These results were supported with an indirect immunofluorescence technique applied to drops of platelet suspensions air-dried on a glass slide. A positive result was obtained with all patients, except one (No. 4) of the two patients without F VIII-RA in their platelets. The other patient was not tested. It is of interest that the patient (No. 11) without F VIII-RA in his platelets is a brother of patient No. 15, suggesting that the absence of F VIII-RA in platelets of patients with VWD is not hereditary.

F VIII-RA from normal human platelets was purified by gel chromatography according to van Mourik and Mochtar (Fig. 1). Both F VIII-RA and VWF-activity were detected in the void volume (V0) fractions from these columns, which is in agreement with observations for plasma factor VIII. Figure 1 shows the results for the chromatogram of VWD platelets. In 3 experiments, the V0 fractions contained both F VIII-RA and VWF-activity, whereas no VWF-activity and F VIII-RA was detected in the V0 of VWD platelet lysates containing no F VIII-RA.

These results indicate that although F VIII-RA is reduced or absent in the plasma of VWD patients, F VIII-RA can be detected in the platelets of most of these patients.

Two reports in the literature are in conflict with our results. Howard et al.4 failed to demonstrate any F VIII-RA in the platelets of one patient with severe VWD and Coller et al.4 found platelets from two patients to be negative in immunofluorescence studies. Shearn et al., however, comparing five different heterologous antifactor VIII antisera found that the platelets from one patient with severe VWD were positive with four of the five antisera using an immunofluorescence technique. The presence of the antigen was also demonstrated by cross immunoelectrophoresis. It should be noted that these studies were performed with a very limited number of patients, whereas the techniques used also differ from ours. One explanation for the discrepant results, may be contamination of the antifactor VIII sera...
with antibodies produced in rabbits against platelet fragments, which may be carried along in the purification of factor VIII. The following observations suggest that in our experiments the antigen detected by rabbit anti-factor VIII in platelets is indeed F VIII-RA.

(1) The platelet antigen could not be distinguished from plasma factor VIII when tested in immunodiffusion and cross immunoelectrophoresis, using antifactor VIII and the antiserum against the low ionic strength components of factor VIII.

(2) The positive immunofluorescence of haemostatic plugs was completely blocked by absorption of antifactor VIII with purified factor VIII, the characteristics of which have been described in detail.\(^{15,16}\)

(3) In preliminary experiments antibodies were prepared against normal and VWD platelet F VIII-RA. These antisera precipitated with purified factor VIII when tested in immunodiffusion experiments.

Previously it has been suggested that the capacity to synthesise F VIII-RA is reduced in VWD. This was concluded from the fact that F VIII-RA is reduced or absent in plasma of patients with VWD. Our findings, however, suggest that the platelets, or more likely the megakaryocytes retain the capacity to synthesise F VIII-RA. Another possible explanation for the presence of F VIII-RA in VWD platelets is that the platelets selectively sequester F VIII-RA from an extracellular source such as plasma or endothelial cells. The fact that F VIII-RA from normal as well from VWD platelets supports ristocetin-induced aggregation may indicate that platelet F VIII-RA is also identical to VWF. VWF has been deemed necessary for normal haemostasis because patients with VWD who lack this factor have a prolonged bleeding time. The presence of F VIII-RA in haemostatic plugs, and blood platelets suggests that it serves some useful function in haemostasis. A direct haemostatic role of platelet F VIII-RA seems unlikely because it is not released from intact platelets and is present in platelets of patients with VWD who have prolonged bleeding times. Although plasma F VIII-RA seems to be more important in haemostatic plug formation the presence and synthesis of F VIII-RA in endothelial cells and its localisation in blood platelets suggest additional haemostatic functions for this molecule.

We thank Dr Jean Dodds for criticising this manuscript. This investigation was supported in part by the Foundation for Medical Research (Fungo) which is subsidised by the Netherlands Organization for the Advancement of Pure Research (ZWO).

### Table 1 Platelet factor VIII-related antigen (F VIII-RA) in VWD

| Patient | FVIII-RA/mg platelet protein | FVIII-RA/(10^10) platelets | FVIII activity plasma (U ml⁻¹) | FVIII-RA plasma (U ml⁻¹) | Bleeding time (min) |
|---------|-----------------------------|--------------------------|----------------------------|--------------------------|------------------|
| 1       | 0.18                        | 35                       | 0.14                       | < 0.05                   | 7                |
| 2       | 0.14                        | 56                       | 0.23                       | < 0.05                   | 9                |
| 3       | 0.04                        | 16                        | 0.13                       | < 0.05                   | 7                |
| 4       | < 0.01                      | < 0.01                    | 0.12                       | < 0.05                   | 15               |
| 5       | 0.15                        | 35                       | 0.11                       | < 0.05                   | ---              |
| 6       | 0.27                        | 60                       | 0.05                       | < 0.05                   | 15               |
| 7       | 0.18                        | 72                       | 0.15                       | < 0.05                   | 15               |
| 8       | 0.26                        | 67                       | 0.12                       | < 0.05                   | 10               |
| 9       | 0.23                        | 90                       | 0.18                       | < 0.05                   | ---              |
| 10      | 0.24                        | 47                       | 0.44                       | 0.80                     | > 15             |
| 11      | < 0.01                      | < 0.01                    | 0.15                       | 0.10                     | ---              |
| 12      | 0.08                        | 14                       | 0.10                       | 0.10                     | ---              |
| 13      | 0.14                        | 38                       | 0.11                       | 0.05                     | ---              |
| 14      | 0.36                        | 120                      | 0.35                       | 0.40                     | 9                |
| 15      | 0.16                        | 34                       | 0.21                       | 0.25                     | 6                |

---

Corrigendum

In the article "The origin of nuclei and of eukaryotic cells" by T. Cavalier-Smith (Nature, 256, 463; 1975) the two unlabelled arrows at the top right of Fig. 5 should read (from the top) Prasinophyta and Charophyta, respectively.

Erratum

In the article by B. Donzel and M. Goodman (Nature, 256, 750; 1975) the title should have read "Synthesis and conformations of hypothalamic hormone releasing factors: two TRF analogues containing backbone N-methyl groups" and not as printed.

© 1975 Nature Publishing Group